Company profile
Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04422912 | phase1_2 | recruiting | 2020-09-29 | 2029-01-01 | Cabaletta Bio | A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) |
| NCT05451212 | phase1 | completed | 2022-11-23 | 2025-07-24 | Cabaletta Bio | Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis |
| NCT06359041 | phase1_2 | recruiting | 2024-12-17 | 2029-09-01 | Cabaletta Bio | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis |
| NCT07006805 | phase1_2 | withdrawn | 2026-06-01 | 2028-09-01 | Cabaletta Bio | RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis |
| NCT06154252 | phase2_3 | recruiting | 2023-12-20 | 2028-07-01 | Cabaletta Bio | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy |
FDA applications (0)
No records yet.